November 12, 2026

To, The Department of Corporate Services, **BSE Limited,** Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400001 **Scrip Code – 544709**	To, The Listing Department, **National Stock Exchange of India Limited,** Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 **Symbol – GAUDIUMIVF**
ISIN: INE0P8B01020	**ISIN:** INE0P8B01020

Subject: Press Release on Unaudited Financial Results for the quarter and half year ended September 30, 2026

Dear Sir/Ma'am,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in terms of other applicable laws, if any, please find enclosed Press Release on Unaudited Financial Results for the quarter and half year ended September 30, 2026.

The above is being made available on the Company's website i.e. www.gaudiumivfcentre.com.

This is for your information, records and appropriate dissemination.

Thanking you,

Yours faithfully

For and on behalf of Gaudium IVF and Women Health Limited

NAVEEN KUMAR
Digitally signed by NAVEEN KUMAR
Date: 2026.11.12 21:03:34 +05'30'

Naveen Kumar
Company Secretary and Compliance Officer
Membership No: A69788

Encl: a/a

Q2 & H1 FY27 EARNINGS PRESS RELEASE

Gaudium IVF reports Q2 FY27 revenue of ₹37.4 crore, up 17.9% YoY; two new IVF hubs operational at South Extension and Gurgaon under planned 19-centre expansion

New Delhi, 12th November, 2026: Gaudium IVF and Women Health Limited, a leading fertility and women's healthcare platform in India, announced its unaudited financial results today for the quarter and half year ended 30th September 2026.

₹ Crore

Financial Summary	Q2 FY27	Q2 FY26	YoY%	H1 FY27	H1 FY26	YoY%
Revenue from Operations	37.4	31.7	17.9%	56.8	49.5	14.7%
EBITDA	13.5	13.8	(2.1)%	15.9	19.0	(16.1)%
EBITDA Margin	***36.0%***	*43.4%*	*(737) bps*	***28.0%***	*38.3%*	*(1030) bps*
PAT	9.4	9.4	0.4%	11.2	12.5	(10.5)%
PAT Margin	***25.2%***	*29.6%*	*(440) bps*	***19.7%***	*25.3%*	*(556) bps*

Key Financial Highlights

Q2 FY27

- **Revenue** grew 17.9% YoY to ₹37.4 Cr, supported by seasonally stronger patient volumes at mature hubs and initial contribution from the new South Extension hub.
- **EBITDA** stood at ₹13.5 Cr, with margin at 36.0%. The quarter absorbed one-off rollout expenses for the two new hubs at South Extension and Gurgaon, along with the higher fixed-cost base of new hubs in their initial ramp-up phase.
- **PAT** stood at ₹9.4 Cr, up 0.4% YoY, with margin at 25.2%.

H1 FY27

- **Revenue** at ₹56.8 Cr, up 14.7% YoY
- **EBITDA** at ₹15.9 Cr; margin at 28.0%
- **PAT** at ₹11.2 Cr; margin at 19.7%

Key Operational Highlights

- **South Extension hub, New Delhi:** Commenced commercial operations on 16th July 2026, the first milestone of the planned 19-centre expansion under the IPO objects. The centre houses the Gaudium Signature Lab with AI-powered embryology tools SiD and ERICA.
- **Gurgaon hub, Haryana:** Commenced commercial operations on 24th September 2026 at Civil Lines, Gurugram, the second new hub of FY27, built on the Gaudium Signature Lab framework.

Key Metrics

- As on 30th September 2026, the Company operates a network of 9 hubs and 28 spokes, with a clinical pregnancy success rate of 62% on the first IVF attempt.

Commenting on the results, Dr. Manika Khanna, Chairperson and Managing Director, Gaudium IVF and Women Health Limited said*:*

> *"In Q2 FY27, revenue from operations stood at ₹37.4 crore, up 17.9% year-on-year, taking H1 FY27 revenue to ₹56.8 crore. Q2 is seasonally one of our stronger quarters, and patient volumes at our mature hubs picked up as expected. Reported EBITDA of ₹13.5 crore reflects one-off rollout expenses for the two hubs we launched this quarter, while margins in our existing IVF business remain stable. New hubs also carry a relatively high fixed cost in their initial phase, as clinical teams, laboratory infrastructure and premises are in place ahead of patient volumes. This will weigh on consolidated margins until each hub matures, after which operating leverage should start to kick in.*
>
> *During the quarter, we commenced operations at two new IVF hubs under our IPO expansion programme: South Extension, New Delhi, in July and Gurgaon, Haryana, in September. Both centres house our Gaudium Signature Lab, bringing AI-led embryology through SiD and ERICA, internationally benchmarked laboratory standards and our standardised clinical protocols to every patient. Our historical new hubs have broken even within about three to six months of launch, and we expect both centres South ex and Gurgaon to follow a similar trajectory.*
>
> *Historically, H1 has been the leaner half for us, with H2 contributing the larger share of annual revenue as Q4 is typically our strongest quarter. With mature hubs continuing to grow, the new hubs scaling up and more centres coming on stream in H2, we expect a stronger second half."*

About Gaudium IVF and Women Health Limited

Founded in 2009, Gaudium IVF and Women Health Limited is a leading fertility and women's healthcare provider in India, offering advanced reproductive solutions and holistic care to women and couples. With centres across Delhi, Mumbai, Bangalore, Patna, Ludhiana, and Srinagar, Gaudium IVF provides a comprehensive suite of services, including IVF, ICSI, IUI, fertility preservation, infertility treatments, advanced genetic testing, high-risk pregnancy care, and minimally invasive gynecological procedures supported by integrated pregnancy care and 24/7 patient services.

Led by its Chairperson and Managing Director, Dr. Manika Khanna who is an internationally trained infertility specialist, Gaudium IVF combines global expertise with state-of-the-art technology and personalized treatment protocols to deliver trusted clinical outcomes. Committed to ethical, accessible, and patient-centric care, Gaudium IVF also drives impact through the Gaudium Foundation, promoting women's health, empowerment, and equality.

For more information, please contact

Company:	Investor Relations (IR):
GAUDIUM IVF AND WOMEN HEALTH LIMITED	**ADFACTORS PR PVT. LTD.**
Mr. Rakesh Kumar Sharma Chief Financial Officer cfo@gaudiumivfcentre.com	**Rushabh Shah / Anand Venugopal** rushabh.shah@adfactorspr.com / anand.venugopal@adfactorspr.com